Parkinson resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 19: Line 19:
**Low [[norepinephrine]] levels
**Low [[norepinephrine]] levels
**The presence of [[Lewy bodies]]
**The presence of [[Lewy bodies]]
**Autoimmune factors
**[[Autoimmunity|Autoimmune]] factors


==Diagnosis==
==Diagnosis==
Shown below is an [[Algorithm (medical)|algorithm]] summarizing the [[diagnosis]] of [[Gait abnormality|Parkinson's disease]] according to the American Academy of Neurology guidelines:<ref name="Marinode Souza2020">{{cite journal|last1=Marino|first1=Bianca L.B.|last2=de Souza|first2=Lucilene R.|last3=Sousa|first3=Kessia P.A.|last4=Ferreira|first4=Jaderson V.|last5=Padilha|first5=Elias C.|last6=da Silva|first6=Carlos H.T.P.|last7=Taft|first7=Carlton A.|last8=Hage-Melim|first8=Lorane I.S.|title=Parkinson’s Disease: A Review from Pathophysiology to Treatment|journal=Mini-Reviews in Medicinal Chemistry|volume=20|issue=9|year=2020|pages=754–767|issn=13895575|doi=10.2174/1389557519666191104110908}}</ref><br><br>
Shown below is an [[Algorithm (medical)|algorithm]] summarizing the [[diagnosis]] of [[Gait abnormality|Parkinson's disease]] according to the American Academy of Neurology guidelines:<ref name="Marinode Souza2020">{{cite journal|last1=Marino|first1=Bianca L.B.|last2=de Souza|first2=Lucilene R.|last3=Sousa|first3=Kessia P.A.|last4=Ferreira|first4=Jaderson V.|last5=Padilha|first5=Elias C.|last6=da Silva|first6=Carlos H.T.P.|last7=Taft|first7=Carlton A.|last8=Hage-Melim|first8=Lorane I.S.|title=Parkinson’s Disease: A Review from Pathophysiology to Treatment|journal=Mini-Reviews in Medicinal Chemistry|volume=20|issue=9|year=2020|pages=754–767|issn=13895575|doi=10.2174/1389557519666191104110908}}</ref>
 




Line 71: Line 72:
{{familytree | | |!| | | | | | | | | }}  
{{familytree | | |!| | | | | | | | | }}  
{{familytree | | A01 | | | | | | |A01=Confirmation of [[Parkinson disease]] [[diagnosis]]}}  
{{familytree | | A01 | | | | | | |A01=Confirmation of [[Parkinson disease]] [[diagnosis]]}}  
{{Family tree/end}}<br>
{{Family tree/end}}(DO NOT MODIFY)<br>
 
 
==Treatment==
==Treatment==
Shown below is an algorithm summarizing the treatment of <nowiki>[[disease name]]</nowiki> according the the [...] guidelines.
Shown below is an [[Algorithm (medical)|algorithm]] summarizing the [[treatment]] of [[Gait abnormality|Parkinson's disease]] according to the American Academy of Neurology guidelines:<ref name="Marinode Souza2020" /><br><br>
<br><br>
{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree | | | | | | | | A01 |A01=[[Parkinson disease]] [[Motor disorders|motor symptoms]]<br>• [[Bradykinesia]] with or without rigidity<br>• [[Tremor]] }}  
{{familytree | | | | | | | | A01 |A01=[[Parkinson disease]] [[Motor disorders|motor symptoms]]<br>• [[Bradykinesia]] with or without rigidity<br>• [[Tremor]] }}  
Line 115: Line 113:
[[deep brain stimulation]]
[[deep brain stimulation]]
([[thalamus]]) }}
([[thalamus]]) }}
{{familytree/end}}
{{familytree/end}}(DO NOT MODIFY)


==Do's==
==Do's==


* Use [[levodopa]] preparations, [[dopamine agonists]], and [[Monoamine oxidase B|monoamine oxidase-B (MAO-B)]] inhibitors initially for [[Motor disorders|motor symptoms]].<ref name="Marinode Souza2020" />
*Use [[levodopa]] preparations, [[dopamine agonists]], and [[Monoamine oxidase B|monoamine oxidase-B (MAO-B)]] inhibitors initially for [[Motor disorders|motor symptoms]].<ref name="Marinode Souza2020" />
* Be aware of [[cognitive impairment]] and other [[side effects]] when using [[Anticholinergic drug|anticholinergic agents]] in young people.<ref name="FoxKatzenschlager2018">{{cite journal|last1=Fox|first1=Susan H.|last2=Katzenschlager|first2=Regina|last3=Lim|first3=Shen-Yang|last4=Barton|first4=Brandon|last5=de Bie|first5=Rob M. A.|last6=Seppi|first6=Klaus|last7=Coelho|first7=Miguel|last8=Sampaio|first8=Cristina|title=International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease|journal=Movement Disorders|volume=33|issue=8|year=2018|pages=1248–1266|issn=08853185|doi=10.1002/mds.27372}}</ref>
*Be aware of [[cognitive impairment]] and other [[side effects]] when using [[Anticholinergic drug|anticholinergic agents]] in young people.<ref name="FoxKatzenschlager2018">{{cite journal|last1=Fox|first1=Susan H.|last2=Katzenschlager|first2=Regina|last3=Lim|first3=Shen-Yang|last4=Barton|first4=Brandon|last5=de Bie|first5=Rob M. A.|last6=Seppi|first6=Klaus|last7=Coelho|first7=Miguel|last8=Sampaio|first8=Cristina|title=International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease|journal=Movement Disorders|volume=33|issue=8|year=2018|pages=1248–1266|issn=08853185|doi=10.1002/mds.27372}}</ref>
* Prescribe an appropriate [[exercise]] regimen at the time of [[diagnosis]] and throughout the [[disease]].<ref name="Marinode Souza2020" />
*Use [[rivastigmine]] for [[Parkinson disease]] [[dementia]]. There is no evidence of [[memantine]] usefulness for mild [[cognitive impairment]].<ref name="SeppiRay Chaudhuri2019">{{cite journal|last1=Seppi|first1=Klaus|last2=Ray Chaudhuri|first2=K.|last3=Coelho|first3=Miguel|last4=Fox|first4=Susan H.|last5=Katzenschlager|first5=Regina|last6=Perez Lloret|first6=Santiago|last7=Weintraub|first7=Daniel|last8=Sampaio|first8=Cristina|last9=Chahine|first9=Lana|last10=Hametner|first10=Eva‐Maria|last11=Heim|first11=Beatrice|last12=Lim|first12=Shen‐Yang|last13=Poewe|first13=Werner|last14=Djamshidian‐Tehrani|first14=Atbin|title=Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review|journal=Movement Disorders|volume=34|issue=2|year=2019|pages=180–198|issn=0885-3185|doi=10.1002/mds.27602}}</ref>
* Use [[deep brain stimulation]] and other [[Surgeries|surgical]] approaches when individuals with [[Parkinson's disease|Parkinson disease]] experience either the “wearing off” phenomenon or [[Dyskinesia|dyskinesias]] that do not respond to [[medication]].<ref name="Marinode Souza2020" />
*Use [[selective serotonin reuptake inhibitors]], [[SSNRI|selective serotonin norepinephrine reuptake inhibitors]], and [[tricyclic antidepressants]] for [[depression]] in [[Parkinson disease]].<ref name="SeppiRay Chaudhuri2019" />
*Use [[anticholinergics]], [[amantadine]], [[dopamine agonists]], [[Monoamine oxidase B|MAO-B inhibitors]] for [[psychosis]] in [[Parkinson's disease|Parkinson disease]].<ref name="SeppiRay Chaudhuri2019" />
*Use [[fludrocortisone]], [[midodrine]], and [[droxidopa]] are all possibly useful for [[orthostatic hypotension]] in [[Parkinson's disease|Parkinson disease]].<ref name="SeppiRay Chaudhuri2019" />
*Prescribe an appropriate [[exercise]] regimen at the time of [[diagnosis]] and throughout the [[disease]].<ref name="Marinode Souza2020" />
*Use [[deep brain stimulation]] and other [[Surgeries|surgical]] approaches when individuals with [[Parkinson's disease|Parkinson disease]] experience either the “wearing off” phenomenon or [[Dyskinesia|dyskinesias]] that do not respond to [[medication]].<ref name="Marinode Souza2020" />


==Don'ts==
==Don'ts==


*The content in this section is in bullet points.
*Do not use [[neuroimaging]] or [[genetic screening]] for  [[Parkinson's disease|Parkinson's disease]] [[diagnosis]].<ref name="SuchowerskyReich2006">{{cite journal|last1=Suchowersky|first1=O.|last2=Reich|first2=S.|last3=Perlmutter|first3=J.|last4=Zesiewicz|first4=T.|last5=Gronseth|first5=G.|last6=Weiner|first6=W. J.|title=Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review)|journal=Neurology|volume=66|issue=7|year=2006|pages=968–975|issn=0028-3878|doi=10.1212/01.wnl.0000215437.80053.d0}}</ref>
*Do not confuse [[Parkinson's disease|Parkinson's disease]] with a [[Parkinsonism|parkinsonian syndrome]]. Distinguish them by performing a dopaminergic challenge with either [[levodopa]] or [[apomorphine]].<ref name="AlbaneseBonuccelli2001">{{cite journal|last1=Albanese|first1=Alberto|last2=Bonuccelli|first2=Ubaldo|last3=Brefel|first3=Christine|last4=Chaudhuri|first4=K. Ray|last5=Colosimo|first5=Carlo|last6=Eichhorn|first6=Tobias|last7=Melamed|first7=Eldad|last8=Pollak|first8=Pierre|last9=Van Laar|first9=Teus|last10=Zappia|first10=Mario|title=Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease|journal=Movement Disorders|volume=16|issue=2|year=2001|pages=197–201|issn=0885-3185|doi=10.1002/mds.1069}}</ref><ref name="pmid10410742">{{cite journal |vauthors=Hughes AJ |title=Apomorphine test in the assessment of parkinsonian patients: a meta-analysis |journal=Adv Neurol |volume=80 |issue= |pages=363–8 |date=1999 |pmid=10410742 |doi= |url=}}</ref>


==References==
==References==

Revision as of 06:33, 27 January 2021


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Moises Romo, M.D.

Synonyms and keywords:Parkinson's disease management, Parkinson's disease workup, Parkinson's disease approach, approach to Parkinson's disease, Parkinson's disease treatment

Overview

Parkinson's disease is a degenerative movement disorder of the central nervous system. It is characterized by motor symptoms such as bradykinesia, rigidity, and tremor, but also cognitive and comunicative symptoms such as facial masking and dysarthria. These primary symptoms are the results of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine. Diagnosis is mainly clinical, it may be supported by MRI findings and dopamine transporter single-photon emission computed tomography (DaT SPECT), but definitive diagnosis is made by autopsy. The mainstay of therapy for motor symptoms of Parkinson disease are: Levodopa, dopamine agonists, monoamine oxidase (MAO) B inhibitors, anticholinergic agents, amantadine, catechol-O-methyl transferase (COMT) inhibitors, estrogen and other drugs such as Exenatide, uric acid, isradipine, nilotinib and GDNF infusion. Other therapies will depend on comorbidities.

Causes

Life Threatening Causes

Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Diagnosis

Shown below is an algorithm summarizing the diagnosis of Parkinson's disease according to the American Academy of Neurology guidelines:[1]


Template:Familytr

 
 
 
 
 
 
 
 
 
 
Prodromal period
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Possible early symptoms of Parkinson disease


Rapid eye movement sleep behavior disorder
Autonomic symptoms (eg, constipation, orthostatic hypotension)


Hyposmia
 
 
 
 
 
 
 
 
Family history


• First-degree relative with Parkinson disease


• Known Parkinson disease gene mutation in family
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical examination
Findings must include


Bradykinesia
• Rigidity and/or tremor
Findings may include
• Hypophonia
• Micrographia
• Decreased arm swing


• Short step length
 
 
Patient medical history
Symptoms may include


Slowness
Tremor
Gait changes
• Soft voice
• Decreased facial expression


Depression and/or anxiety
 
 
Other factors
Dopamine transporter single-proton emission computed tomography imaging findings
Genetic data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluation consistent with Parkinson disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment of features potentially indicative of atypical parkinsonism


• Rapid progression
• Early and recurrent falls
• Severe early dysphonia or dysarthria
• Severe early autonomic failure


Cerebellar findings (eg, dysmetria)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All features present?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluate for patient response to levodopa
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Response?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
 
 
No
 
 
 
Consider diagnosis of atypical parkinsonism
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confirmation of Parkinson disease diagnosis
 
 
 
 
 
 

(DO NOT MODIFY)

Treatment

Shown below is an algorithm summarizing the treatment of Parkinson's disease according to the American Academy of Neurology guidelines:[1]

 
 
 
 
 
 
 
Parkinson disease motor symptoms
Bradykinesia with or without rigidity
Tremor
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial medical therapy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tremor and/or bradykinesia options


Levodopa preparations
Dopamine agonists
Monoamine oxidase-B

inhibitors
 
 
 
 
 
 
 
Tremor only


Anticholinergic agents

(eg, trihexyphenidyl)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subsequent medical therapy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increasing doses and add-on therapies for “wearing off”


Levodopa preparations
• Istradefylline
Dopamine agonists
Monoamine oxidase B inhibitors
Catechol-O-methyltransferase inhibitors
Amantadine

(primarily for dyskinesia)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Advanced therapy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tremor and/or bradykinesia options
 
 
 
 
 
Tremor only
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Levodopa carbidopa

enteral suspension infusion
• Unilateral or bilateral

deep brain stimulation
 
 
 
 
 
• Unilateral focused

ultrasound thalamotomy
• Unilateral or bilateral deep brain stimulation

(thalamus)

(DO NOT MODIFY)

Do's

Don'ts

References

  1. 1.0 1.1 1.2 1.3 1.4 Marino, Bianca L.B.; de Souza, Lucilene R.; Sousa, Kessia P.A.; Ferreira, Jaderson V.; Padilha, Elias C.; da Silva, Carlos H.T.P.; Taft, Carlton A.; Hage-Melim, Lorane I.S. (2020). "Parkinson's Disease: A Review from Pathophysiology to Treatment". Mini-Reviews in Medicinal Chemistry. 20 (9): 754–767. doi:10.2174/1389557519666191104110908. ISSN 1389-5575.
  2. Fox, Susan H.; Katzenschlager, Regina; Lim, Shen-Yang; Barton, Brandon; de Bie, Rob M. A.; Seppi, Klaus; Coelho, Miguel; Sampaio, Cristina (2018). "International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease". Movement Disorders. 33 (8): 1248–1266. doi:10.1002/mds.27372. ISSN 0885-3185.
  3. 3.0 3.1 3.2 3.3 Seppi, Klaus; Ray Chaudhuri, K.; Coelho, Miguel; Fox, Susan H.; Katzenschlager, Regina; Perez Lloret, Santiago; Weintraub, Daniel; Sampaio, Cristina; Chahine, Lana; Hametner, Eva‐Maria; Heim, Beatrice; Lim, Shen‐Yang; Poewe, Werner; Djamshidian‐Tehrani, Atbin (2019). "Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review". Movement Disorders. 34 (2): 180–198. doi:10.1002/mds.27602. ISSN 0885-3185.
  4. Suchowersky, O.; Reich, S.; Perlmutter, J.; Zesiewicz, T.; Gronseth, G.; Weiner, W. J. (2006). "Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review)". Neurology. 66 (7): 968–975. doi:10.1212/01.wnl.0000215437.80053.d0. ISSN 0028-3878.
  5. Albanese, Alberto; Bonuccelli, Ubaldo; Brefel, Christine; Chaudhuri, K. Ray; Colosimo, Carlo; Eichhorn, Tobias; Melamed, Eldad; Pollak, Pierre; Van Laar, Teus; Zappia, Mario (2001). "Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease". Movement Disorders. 16 (2): 197–201. doi:10.1002/mds.1069. ISSN 0885-3185.
  6. Hughes AJ (1999). "Apomorphine test in the assessment of parkinsonian patients: a meta-analysis". Adv Neurol. 80: 363–8. PMID 10410742.


Template:WikiDoc Sources